6:07 PM
 | 
Oct 22, 2012
 |  BC Extra  |  Clinical News

Lilly's dulaglutide meets Phase III endpoints

Eli Lilly and Co. (NYSE:LLY) said once-weekly dulaglutide met the primary endpoints in three Phase III trials to treat Type II diabetes. In 978 diabetics on metformin and pioglitazone in the AWARD-1 trial, dulaglutide significantly reduced HbA1c from baseline to week 26 vs....

Read the full 203 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >